Myriad Genetics, Inc. MYGN

Company Overview

Myriad Genetics, Inc. is a U.S.-based molecular diagnostics and genetic testing company focused on precision medicine, hereditary disease risk assessment, oncology testing, reproductive health screening, and mental health pharmacogenomics. The company develops and commercializes genetic tests that help healthcare providers assess disease risk, guide treatment decisions, and support patient management across oncology, women’s health, and mental health care. Myriad operates primarily within the biotechnology, molecular diagnostics, and healthcare technology industries, with revenue largely generated through clinical genetic testing services reimbursed by insurers, healthcare systems, and patients.

Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad initially gained prominence through its hereditary cancer testing business, particularly BRCA-related diagnostics. Over time, the company expanded beyond hereditary cancer screening into broader precision medicine offerings through internal development and acquisitions. Its portfolio now includes oncology diagnostics, prenatal and reproductive testing, companion diagnostics, and mental health-related pharmacogenomic testing. Myriad’s strategic positioning has historically been supported by its large proprietary genetic database, established payer relationships, laboratory infrastructure, and long-standing presence in clinical genomics.

Business Operations

Myriad organizes its operations around multiple diagnostic testing categories, including hereditary cancer testing, oncology precision medicine, women’s health, and mental health diagnostics. Key commercial offerings include the myRisk Hereditary Cancer Test, GeneSight Psychotropic, Prequel Prenatal Screen, and Precise Tumor profiling solutions. Revenue is generated primarily through laboratory testing services billed to commercial insurers, government healthcare programs, integrated delivery networks, and individual patients. The company also participates in companion diagnostic collaborations with pharmaceutical companies supporting targeted therapies and clinical development programs.

The company maintains laboratory and operational infrastructure primarily in the United States while serving clinicians and patients internationally through select partnerships and distribution arrangements. Myriad has historically controlled significant genomic datasets and proprietary variant interpretation capabilities that support test accuracy and clinical reporting. Major business developments have included the acquisition of Counsyl, which expanded reproductive health testing capabilities, and Gateway Genomics, known for consumer prenatal testing offerings. Myriad has also maintained partnerships with healthcare providers, pharmaceutical firms, and research organizations focused on precision oncology and personalized medicine applications.

Strategic Position & Investments

Myriad’s strategic direction centers on expanding precision medicine adoption, increasing utilization of genetic testing in standard clinical care, and strengthening reimbursement coverage across its diagnostic portfolio. The company has invested in oncology-focused technologies, hereditary disease screening, and pharmacogenomic applications intended to support individualized treatment decisions. Growth initiatives have included broadening physician access, integrating artificial intelligence and bioinformatics into genomic interpretation workflows, and expanding evidence-generation studies to support payer and clinical adoption.

Acquisition activity has played a meaningful role in portfolio expansion. The acquisition of Counsyl strengthened Myriad’s reproductive health business, while the purchase of Gateway Genomics added direct-to-consumer prenatal testing capabilities. The company has also pursued investments in companion diagnostics and molecular residual disease research through collaborations and internal development efforts. Strategic emphasis has increasingly focused on integrating genomic insights into mainstream healthcare delivery while improving operational efficiency and expanding high-margin testing categories.

Geographic Footprint

Myriad Genetics is headquartered in Salt Lake City, Utah, with primary laboratory and operational facilities located in the United States. The company’s core commercial presence remains concentrated in North America, particularly within the U.S. healthcare market, where it serves oncologists, obstetricians, genetic counselors, psychiatrists, and large health systems. Its testing services are supported by relationships with national and regional payers, hospital networks, and physician groups.

Outside the United States, Myriad has maintained selective international operations and commercial relationships in regions including Europe, Canada, and parts of the Asia-Pacific market. International expansion has generally occurred through distribution agreements, licensing arrangements, and clinical collaborations rather than large-scale owned laboratory infrastructure abroad. The company’s influence in global precision medicine has primarily stemmed from its genomic databases, clinical evidence programs, and participation in multinational research and pharmaceutical partnerships.

Leadership & Governance

Myriad Genetics operates under a corporate governance structure led by a board of directors and executive leadership team focused on clinical innovation, operational efficiency, and precision medicine commercialization. The company’s leadership strategy has emphasized expanding access to genomic testing, improving payer reimbursement alignment, and strengthening the integration of molecular diagnostics into routine clinical workflows. Public filings and investor communications have consistently highlighted a focus on evidence-based medicine, technology-enabled diagnostics, and sustainable growth within regulated healthcare markets.

Key executives include:

• Sam Raha – President and Chief Executive Officer
• Bryan Riggsbee – Chief Financial Officer
• Rick T. Carlson – Chief Operating Officer
• Dr. George Daneker Jr. – Chief Clinical Officer
• Melissa Gonzales – Chief People Officer
• Nicole Lambert – Chief Legal Officer and Corporate Secretary

Certain executive roles and leadership assignments have changed periodically through corporate restructuring and strategic transitions. Data reflects publicly available company disclosures and regulatory filings available during recent reporting periods.